Onyx @ Union Square: Shankar Musunuri, CEO, Ocugen
What if the key to curing blindness wasn't targeting individual genes, but entire genetic networks?
Ocugen has a cure in sight... will it get FDA approval soon?
“The cost of gene therapies can reach millions of dollars per patient… Our goal is developing cost-effective treatments that can be accessible globally.”